Barely two months after voters in the state passed the legalization ballot, the first legal recreational cannabis products have been sold in Arizona.
As the study was purely observational, the researchers do not suggest any type of causality or mechanism behind these associations. But they do recommend further studies to help inform policy and treatment decisions.
Researchers from New York University found that relative usage rates of cannabis were up 13 percent at the end of each year compared to the first quarter.
Based on these promising results, the study’s authors say that CBD could form the basis of a new class of antibiotics, the first for resistant bacteria in 60 years.
In a win for hemp farmers, the final rule widens the margin of error for THC levels in hemp plants before a cultivator is declared criminally negligent. However, several high-profile sticking points remain, including some guidelines on sampling.
The federal study aims to improve the testing standards used throughout the cannabis lab sector. Any lab interested in participating in the next phase of the project has until February 5 to enroll.
Responding to Analytical Cannabis, ProVerde president Chris Hudalla explained that the Maine lab was “in operation before there were any requirements or mechanisms for licensing of marijuana testing laboratories in Maine.”
The researchers also found that tobacco smokers, and those who smoke a mixture of cannabis and tobacco, had elevated blood levels of acrolein, which is linked to an increased risk of developing heart disease.
Any consumer in possession of such a product has been advised by the Colorado Department of Revenue to return it to the initial retailer.